Matthias Kapturczak, MD
Nephrology · San Antonio, TXNPI 1861429755
Payments from drug & device makers
Across 103 payments — averaging $52.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- CSL Behring$714
- Veloxis Pharmaceuticals, Inc.$641
- Otsuka America Pharmaceutical, Inc.$162
- Mallinckrodt Hospital Products Inc.$153
- Novartis$149
- plus $796 from 13 others
What the payments were for
- Consulting fees$2,74859%
- Food & beverage$1,85240%
- Education$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $2,748 |
| CSL Behring | 11 | $714 |
| Veloxis Pharmaceuticals, Inc. | 29 | $641 |
| Otsuka America Pharmaceutical, Inc. | 10 | $162 |
| Mallinckrodt Hospital Products Inc. | 6 | $153 |
| Novartis | 5 | $149 |
| Celonova Biosciences, Inc. | 1 | $140 |
| Mallinckrodt Enterprises LLC | 9 | $135 |
| Amgen(2 entities) | 6 | $89 |
| AstraZeneca(2 entities) | 5 | $70 |
| Vifor Pharma, Inc. | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| GSK | 3 | $43 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Davol Inc. | 2 | $39 |
| Aurinia Pharma U.S., Inc. | 2 | $35 |
| Travere Therapeutics, Inc. | 2 | $33 |
| One Lambda, Inc. | 1 | $26 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rivfloza$2,748
How this compares
$5,363 in reported general payments places this provider in the 70th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 15 | $10,890 |
| EliquisApixaban | 11 | $8,725 |
| Valganciclovir Hcl | 43 | $8,116 |
| Tacrolimus | 49 | $6,193 |
| XareltoRivaroxaban | 11 | $3,060 |
| Mycophenolate Mofetil | 36 | $3,033 |
| Cyclosporine ModifiedCyclosporine, Modified | 13 | $1,871 |
| Cinacalcet Hcl | 17 | $1,548 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,094 |
| Bumetanide | 15 | $555 |
| Cefdinir | 34 | $541 |
| Fludrocortisone Acetate | 13 | $354 |
| Ondansetron OdtOndansetron | 34 | $345 |
| Nifedipine ErNifedipine | 27 | $330 |
| Tamsulosin Hcl | 28 | $301 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Antonio
- Pablo PergolaSan Antonio$14.2M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Wesley CalhounSan Antonio$3.5M
- Shweta BansalSan Antonio$1.7M
- Robert SzewcSan Antonio$1.5M
- Rashid SharafSan Antonio$661K
- Varshasb BroumandSan Antonio$538K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.